TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Savella in Treatment for Provoked Vestibulodynia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. women between 18-54 years of age,~2. 'Friedrich's Criteria' must be met (report greater than six continuous months of vulvar symptoms including insertional dyspareunia or pain to touch, demonstrate on physical exam moderate to severe tenderness to light touch, localized to the vulvar vestibule \[positive Cotton Swab Test\] and demonstration of variable degrees of erythema of the vestibule),~3. an average pain level of 4 or greater on the 10-point tampon test and/or an average pain level of 4 or greater on the sexual intercourse pain scale(0 = no pain at all; 10 = worse pain ever) during the 2-week screening period(see Study Parameters Section), and~4. willing to use two forms of contraception during the study.~Exclusion Criteria:~1. other vulvar conditions, including dermatoses, vulvitis, vulvar papillomatosis, and atrophic vaginitis (presence of a maturation index),~2. previous vestibulectomy,~3. active vaginal infection,~4. neuropathology, including seizure disorder or syncopal episodes,~5. pregnancy or at risk for pregnancy and not using a reliable birth control method for at least 3 months prior to entering the study,~6. breastfeeding,~7. major medical illness including chronic liver disease/hepatic impairment, renal impairment, narrow-angle glaucoma, or uncontrolled hypertension,~8. major psychiatric illness including substance abuse,~9. multiple allergies (greater than three drugs or environmental agents),~10. use of centrally-acting agents, including monoamine oxidase inhibitors, benzodiazepines, opiates, muscle relaxants, and antidepressants within 2 weeks of randomization and during the study, and~11. use of topical lidocaine, within 2 weeks of randomization and during the study, as it has shown to be an effective treatment in some women, while worsening symptoms in others. Subjects will be permitted to take acetaminophen, aspirin, or a nonsteroidal anti-inflammatory drug as rescue medication. They will be provided with a list of allowable escape medications and those which would constitute a protocol deviation.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 54 Years
- Healthy Volunteers: t

Study Arms:
- Milnacipran (Type: EXPERIMENTAL): This was an 18-week, open-label, flexible-dose exploratory trial where eligible patients were treated with 200 mg/day of milnacipran (or the maximum tolerated dose) for a total of 12 weeks. The study design involved 3 phases: screening and baseline assessment, dose escalation and stable-dose phase. All women received 12 weeks of stable dose treatment after a 6-week dose-escalation period for a total of 18 weeks of drug exposure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of Quadrivalent Influenza Vaccine (NBP607-QIV) in Adults and Elderly Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adults aged 19 years and older~* Those who are able to comply with the requirements for the study~* If women, a negative pregnancy test and willingness to use birth control measures for the entire study duration~Exclusion Criteria:~* Disorders in immune function~* Any malignancy or lymphoproliferative disorder~* History of Guillain-Barré syndrome~* Individuals with a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time~* Experience of fever (\>38.0 ℃) within 24 hours following vaccination~* Body temperature \>38.0 ℃ at the vaccination day~* Concomitant medications/therapy such as immunosuppressants or immune modifying drugs, systemic corticosteroids, immunoglobulins, blood or blood- derived products within 3 months~* Influenza vaccination within 6 months~* Subjects who have participated in other interventional study within 4 weeks~* Any vaccination within 1 month~* Those who are planning to receive any vaccine within 1 month from the study vaccine~* Individuals with any serious chronic or progressive disease~* Pregnant or breast-feeding women~* Any other reason that in the opinion of the investigator might interfere with the study

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- NBP607-QIV (Type: EXPERIMENTAL): Participants aged 19 years and older received a 0.5mL single intramuscular dose of Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine containing 4 virus strains; A/H1N1, A/H3N2, B/Yamagata, B/Victoria on Day 0
- NBP607-Y (Type: ACTIVE_COMPARATOR): Participants aged 19 years and older received a 0.5mL single intramuscular dose of Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Yamagata on Day 0
- NBP607-V (Type: ACTIVE_COMPARATOR): Participants aged 19 years and older received a 0.5mL single intramuscular dose of Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Victoria on Day 0

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of MT-3995 in Patients With Diabetic Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus~* Glycated hemoglobin(HbA1c) values (National Glycohemoglobin Standardization Program : NGSP) ≤10.5%~* estimated glomerular filtration rate(eGFR) of ≥30 mL/min/1.73 m2~* The median UACR of the first morning void urine samples is ≥50 mg/g Cr and \<300 mg/g Cr~* Stable blood pressure(diastolic blood pressure (DBP) \<100 mmHg and stable systolic blood pressure (SBP) \<160 mmHg)~Exclusion Criteria:~* Type 1 diabetes, diabetes resulting from pancreatic injury, or secondary forms of diabetes.~* A diagnosis of non-diabetic renal disease.~* A following serum potassium level.~  * eGFR of 30-59mL/min/1.73m2; serum potassium level of \<3.5 or \>4.7 mmol/L,~ * eGFR of ≥60mL/min/1.73m2: serum potassium level of \<3.5 or \>5.0 mmol/L~* symptomatic and clinically significant hypotension(diastolic blood pressure(DBP)\<50mmHg and systolic blood pressure(SBP)\<110mmHg)~* QT prolongation or torsades de pointes, or, a history or family history of QT prolongation or torsades de pointes~* New York Heart Association (NYHA) Class III or IV heart failure

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- MT-3995 Low (Type: EXPERIMENTAL): None
- MT-3995 Middle (Type: EXPERIMENTAL): None
- MT-3995 High (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Antibody and Safety Study of 6 Doses of NicVAX in Smokers

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy smoker, ≥10 cigarettes per day for 6 months, exhaled carbon monoxide ≥10 ppm~* Written informed consent~* Negative urine pregnancy test, and willing to use birth control during the study, if applicable~Exclusion Criteria:~* Prior exposure to nicotine vaccine~* Clinically significant allergic reactions, especially to components of the vaccine~* Serious or unstable clinical disease within the past 6 months~* Use of any smoking cessation therapy within 30 days preceding 1st dose~* Immunosuppression, due to: steroids or other immunosuppressants in the last 30 days, history of cancer or cancer treatment in the last 60 months, known HIV infection, or congenital or acquired immunodeficiency~* Use of any vaccine other than influenza vaccine within 30 days prior to each study dose~* Use of another IND drug or device within 30 days preceding 1st dose~* Inability to follow the protocol, or illicit drug use in the past 12 months, or psychiatric disorder in the past 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- NicVAX (Type: EXPERIMENTAL): None
- NicVAX Lot 2 (Type: EXPERIMENTAL): 2nd cohort receives a different lot of vaccine from the 1st cohort

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.~Inclusion Criteria:~* Histologically or cytologically confirmed diagnosis of malignant melanoma~* Previously-treated or untreated unresectable Stage III or Stage IV melanoma~* Measurable/evaluable disease per modified World Health Organization (mWHO) criteria, within 28 days of first dose of study drug~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~Exclusion Criteria:~* Active brain metastases~* Primary ocular or mucosal melanoma~* History of or current active autoimmune disease

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: Ipilimumab (Type: EXPERIMENTAL): Ipilimumab Intravenous Injection 3 mg/kg for every 3 weeks upto 4 doses

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adolescents from 10-18 years of age, generally in good health, and available for all study visits, who/whose legally acceptable representative has given written informed consent at the time of enrollment.~* Female subjects of childbearing potential must have a negative urine pregnancy test.~Exclusion Criteria:~* Serious, acute, or chronic illnesses. Previous or suspected disease caused by N. meningitidis. Previous immunization with any meningococcal vaccine.~* Exposure to individuals with clinically proven meningococcal disease or clinical bacterial meningitis without further microbiologic characterization.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- MenABCWY (Type: EXPERIMENTAL): Subjects received one dose of MenABCWY vaccine at day 1 and a second dose after 2 months
- Placebo/MenACWY (Type: ACTIVE_COMPARATOR): Subjects received one dose of placebo at day 1 and one dose of MenACWY vaccine after 2 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Atorvastatin Versus Placebo to Reduce Cardiopulmonary Complications After Thoracic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients ≥ 18 yr. scheduled for anatomic lung resection (segmentectomy, lingulectomy, possible or definite lobectomy, bilobectomy, pneumonectomy or extrapleural pneumonectomy) with or without chest wall resection or limited resection~* Patients with regular cardiac rhythm~* Patients able to take oral capsules~* Patients capable of providing written, informed consent~* Patients without known hepatic or kidney disease~Exclusion Criteria:~* Patients already taking any statin, gemfibrozil (Lopid), or ezetimibe (Zetia)~* Hypersensitivity to atorvastatin~* Chronic atrial fibrillation~* Patients already taking class Ic or III antiarrhythmic drugs~* Known pregnancy a urine pregnancy test will be given to women of childbearing age~* Known history of active hepatic disease or known hepatic insufficiency~* Known history of active kidney disease or insufficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Atorvastatin
- 2 (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of N115 on Coughing in IPF Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Individuals with a clinical diagnosis of idiopathic pulmonary fibrosis in accordance with the most recent collaborative guidelines from the American Thoracic Society, the European Respiratory Society, the Japanese Respiratory Society, and the Latin American Thoracic Association including HRCT scan and/or lung biopsy consistent with unusual interstitial pneumonia (UIP), especially honeycombing, without identifiable cause related to other ILD such as drug toxicity, occupational or environmental exposure or connective tissue disease.~* condition-related cough.~* Mild to moderate FEV1 and FVC at 50% or greater of standard~* Individuals who agree to abstain from sexual intercourse, or agree to use condoms or vaginal diaphragms or other devices designed to prevent contraception, during the entire course of the study.~Exclusion Criteria:~* Pulmonary disease other than idiopathic pulmonary fibrosis.~* Respiratory infections in the last 2 weeks.~* Clinically significant cardiac disease including uncontrolled congestive heart failure and unstable angina.~* Pregnancy (urine pregnancy test will be performed prior to enrollment).~* Females of childbearing potential age not on adequate contraception or lactating females.~* Subjects less than 18 years of age.~* Hospitalization within last 6 months due to acute exacerbation of airway disease.~* Subjects with a clinically significant abnormal chest X-ray within past 12 months.~* Medication changes within 1 month of study entry except for antiviral, antibiotic, or antimicrobial medications as well as corticosteroids, antihistamines, or anti-inflammatory medications.~* Subjects who have participated in another drug treatment study within the last month.~* Subjects with a current history of alcohol or recreational drug abuse.~* Subjects who have taken dietary supplements containing pyruvate within 24 hours prior to the screening visit.~* Subjects with metabolic diseases (diabetes, hypoglycemia, etc.).

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 20mM sodium pyruvate nasal spray treatment (Type: EXPERIMENTAL): None
- Saline placebo control (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Odanacatib (MK-0822) in Participants With Involutional Osteoporosis (MK-0822-022)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal woman (for at least 5 years) or men who are aged between 45 to 85~* Participant who has low bone mineral density~* Participant has anatomy suitable for dual-energy x-ray absorptiometry (DXA) of the lumber spine and hip~* Participant is ambulatory (can walk)~Exclusion Criteria:~* Participant has secondary osteoporosis or has a metabolic bone disorder other than osteoporosis or osteopenia~* Participant has received osteoporosis medications or other medications that affect bone~* Participant is already participating in another drug study

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): After an observation period of \~5 weeks, participants receive dose-matched placebo to odanacatib once weekly for 52 weeks. Participants also receive weekly supplementation with open-label 5600 International Units (IU) vitamin D3 and 500 mg of open-label daily calcium supplement (if calcium \<1000 mg per day from dietary and other sources) throughout the observation and treatment periods.
- Odanacatib 10 mg (Type: EXPERIMENTAL): After an observation period of \~5 weeks, participants receive 10 mg odanacatib once weekly for 52 weeks. Participants also receive weekly supplementation with open-label 5600 IU vitamin D3 and 500 mg of open-label daily calcium supplement (if calcium \<1000 mg per day from dietary and other sources) throughout the observation and treatment periods.
- Odanacatib 25 mg (Type: EXPERIMENTAL): After an observation period of \~5 weeks, participants receive 25 mg odanacatib once weekly for 52 weeks. Participants also receive weekly supplementation with open-label 5600 IU vitamin D3 and 500 mg of open-label daily calcium supplement (if calcium \<1000 mg per day from dietary and other sources) throughout the observation and treatment periods.
- Odanacatib 50 mg (Type: PLACEBO_COMPARATOR): After an observation period of \~5 weeks, participants receive 50 mg odanacatib once weekly for 52 weeks. Participants also receive weekly supplementation with open-label 5600 IU vitamin D3 and 500 mg of open-label daily calcium supplement (if calcium \<1000 mg per day from dietary and other sources) throughout the observation and treatment periods.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: N-Acetyl-Cysteine (NAC) for Healing of Amputation Stumps in the Setting of Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject undergoing elective major (above-knee or below-knee) lower extremity amputation for CLI~* Both male and female patients~* All ethnic groups~* Between of the ages of 30-90 years old~* Adequate nutritional status - defined as BMI \> 19~Exclusion Criteria:~* Pregnant women, and women who are breastfeeding~* Known history of end-stage liver disease~* Severe asthma~* Heavy alcohol consumption (male \> 2 drinks per day and women \> 1 drink per day)~* Individuals actively receiving chemotherapy.~* Anticipated enrollment in another study that investigates another drug agent within 30 days from enrollment in this study.~* Patients receiving carbamazepine.~* Severe anemia (HCT \< 22).~* Allergy to either NAC or Indocyanine Green (ICG).~* Patients with open wound(s) from a prior amputation on the ipsilateral limb (excluding patients who had prior partial foot amputation, who are now requiring a below-knee or above-knee amputation).

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Active Arm N-acetyl cysteine (NAC) (Type: ACTIVE_COMPARATOR): Upon study enrollment, patients will be randomized 1:1 by Investigational Pharmacy to a standard adult intravenous dose of NAC (1200mg twice a day) for 6 days post-amputation.
- Placebo Arm (Type: PLACEBO_COMPARATOR): Upon study enrollment, patients will be randomized 1:1 by Investigational Pharmacy to placebo ½ normal saline infusion (twice a day) for 6 days post-amputation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Icariin for Bipolar Disorder and Co-Occurring Substance Use Disorders

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Current BPD I, II or NOS and cocaine or alcohol use disorder with HAMD score of ≥ 15~* Cocaine or alcohol use with 5 days of initiating study drug~* Men and women~* Age 18-70 years~Exclusion Criteria:~* Psychotic features~* Non-English speakers~* Treatment resistant depression defined as failure of a trial of antidepressants (≥ 4 weeks at a therapeutic dose) in current episode~* Major medical condition including heart, lung, liver or renal disease, cancer, neurological or immunological conditions~* Vulnerable populations including prisoners, cognitively impaired individuals, and pregnant or nursing women~* Prior side effects or allergic reactions to icariin-containing preparations~* Change in psychotropic medications within 14 days of study entry~* Current suicidal ideation (plan and intent), a suicide attempt within the past 12 months or history of \> 1 lifetime suicide attempt

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- icariin (Type: EXPERIMENTAL): Icariin will be given 100 mg/day. A dose titration from 100 mg/day to 200 mg/day will be allowed at week 3 for participants with less than a 30% reduction in HAMD and/or still using cocaine or alcohol or have a positive urine drug screen. An additional dose titration to 300 mg/day will be allowed at week 6 for participants with less than a 50% reduction in HAMD scores and/or still using cocaine or alcohol or have a positive urine drug screen.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete